VNRX

SEC source: 0001477932-25-004367 · form4.xml · nonDerivative · entry 1

Hughes Terig · CIK 0001841309 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 407,627

F1 · shares: On June 1, 2025, the reporting person was awarded 17,406 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 5,802 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-004368 · form4.xml · nonDerivative · entry 2

Retter Andrew · CIK 0002015252 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 142,175

F2 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,784 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-004368 · form4.xml · nonDerivative · entry 1

Retter Andrew · CIK 0002015252 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,773

F1 · shares: On June 1, 2025, the reporting person was awarded 13,069 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,357 units, 4,356 units, and 4,356 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-004366 · form4.xml · nonDerivative · entry 1

Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,283

F1 · shares: On June 1, 2025, the reporting person was awarded 18,341 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 6,114 units, 6,114 units, and 6,113 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-004365 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 404,507

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 47,837 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-004364 · form4.xml · nonDerivative · entry 1

Rubin Ethel · CIK 0002038290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,524

F1 · shares: On June 1, 2025, the reporting person was awarded 11,983 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,995 units, 3,994 units, and 3,994 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-004915 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,466

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 4,828 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-003965 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 426,033

SEC source: 0001477932-25-003959 · form4.xml · nonDerivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,319,222

SEC source: 0001477932-25-003320 · form4.xml · nonDerivative · entry 1

Michel Gaetan · CIK 0001709503 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 388,276

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 13,689 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-003319 · form4.xml · nonDerivative · entry 1

Retter Andrew · CIK 0002015252 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,704

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 8,326 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-003318 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,573

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 12,984 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-003317 · form4.xml · nonDerivative · entry 1

Butera Salvatore Thomas · CIK 0001834339 · CEO, Volition Veterinary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 302,685

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 31,256 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-003316 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,006

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 8,944 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-003314 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 376,033

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 40,709 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

SEC source: 0001477932-25-002073 · form4.xml · nonDerivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,299,222

F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx.

SEC source: 0001477932-25-002072 · form4.xml · nonDerivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 868,689

F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx.

SEC source: 0001477932-25-001466 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,026

F1 · shares: On March 1, 2025, the reporting person was awarded 7,908 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 2,636 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001465 · form4.xml · nonDerivative · entry 1

Plummer Nicholas · CIK 0001880653 · GC - Volition Diagnostics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,628

F1 · shares: On March 1, 2025, the reporting person was awarded 12,483 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 4,161 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001464 · form4.xml · nonDerivative · entry 1

Nguyen Kim · CIK 0001852492 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,409

F1 · shares: On March 1, 2025, the reporting person was awarded 9,893 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,298 units, 3,298 units, and 3,297 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001463 · form4.xml · nonDerivative · entry 1

Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,942

F1 · shares: On March 1, 2025, the reporting person was awarded 14,233 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,745 units, 4,744 units, and 4,744 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001462 · form4.xml · nonDerivative · entry 1

Colman Alan · CIK 0001577873 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 245,364

F1 · shares: On March 1, 2025, the reporting person was awarded 14,840 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,947 units, 4,947 units, and 4,946 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001461 · form4.xml · nonDerivative · entry 1

Kway Jasmine · CIK 0001808135 · CEO - Singapore Volition

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 182,780

F1 · shares: On March 1, 2025, the reporting person was awarded 16,708 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 5,570 units, 5,569 units, and 5,569 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001460 · form4.xml · nonDerivative · entry 1

Retter Andrew · CIK 0002015252 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,617

F1 · shares: On March 1, 2025, the reporting person was awarded 10,142 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,381 units, 3,381 units, and 3,380 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001459 · form4.xml · nonDerivative · entry 1

Rubin Ethel · CIK 0002038290 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,541

F1 · shares: On March 1, 2025, the reporting person was awarded 9,893 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,298 units, 3,298 units, and 3,297 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001458 · form4.xml · nonDerivative · entry 1

Butera Salvatore Thomas · CIK 0001834339 · CEO - Volition Veterinary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 312,890

F1 · shares: On March 1, 2025, the reporting person was awarded 19,300 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 6,434 units, 6,433 units, and 6,433 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001457 · form4.xml · nonDerivative · entry 1

Forterre Gael · CIK 0001841637 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,704

F1 · shares: On March 1, 2025, the reporting person was awarded 5,523 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 1,841 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001456 · form4.xml · nonDerivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 686,871

F1 · shares: On March 1, 2025, the reporting person was awarded 19,786 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 6,596 units, 6,595 units, and 6,595 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-001455 · form4.xml · nonDerivative · entry 1

Hughes Terig · CIK 0001841309 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 390,221

F1 · shares: On March 1, 2025, the reporting person was awarded 13,969 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 4,657 units, 4,656 units, and 4,656 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-25-000615 · form4.xml · derivative · entry 2

Colman Alan · CIK 0001577873 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2029-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000615 · form4.xml · derivative · entry 1

Colman Alan · CIK 0001577873 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2025-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000614 · form4.xml · derivative · entry 2

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000614 · form4.xml · derivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000613 · form4.xml · derivative · entry 2

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,000

Underlying: Common Stock · 25,000 shares

Expires 2029-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000613 · form4.xml · derivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 25,000 shares

Expires 2025-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000612 · form4.xml · derivative · entry 2

Kway Jasmine · CIK 0001808135 · CEO -Singapore Volition

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000612 · form4.xml · derivative · entry 1

Kway Jasmine · CIK 0001808135 · CEO -Singapore Volition

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000611 · form4.xml · derivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000611 · form4.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000610 · form4.xml · derivative · entry 2

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000610 · form4.xml · derivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000609 · form4.xml · derivative · entry 2

Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 40,000

Underlying: Common Stock · 40,000 shares

Expires 2029-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000609 · form4.xml · derivative · entry 1

Batchelor Ann-Louise · CIK 0001945612 · Group Chief Marketing Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Spouse

Disclosed balance after: 0

Underlying: Common Stock · 40,000 shares

Expires 2025-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

SEC source: 0001477932-25-000326 · form4.xml · nonDerivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 667,085

F1 · shares: The reporting person received 50,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, vesting in three installments of 16,667 units, 16,667 units, and 16,666 units on each of January 15, 2026, January 15, 2027 and January 15, 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-24-007972 · form4.xml · nonDerivative · entry 1

Innes Guy Archibald · CIK 0001579377 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 617,085

F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx.

SEC source: 0001477932-24-007971 · form4.xml · nonDerivative · entry 1

STILL TIMOTHY I · CIK 0001200616 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,487,382

F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx.

SEC source: 0001477932-24-007970 · form4.xml · nonDerivative · entry 1

Micallef Jacob Vincent · CIK 0001651671 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 394,352

F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx.

SEC source: 0001477932-24-007969 · form4.xml · nonDerivative · entry 1

Reynolds Cameron John · CIK 0001340610 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,117,404

F1 · shares: Acquired at the offering price in the registered direct offering of Common Stock by VolitionRx.

SEC source: 0001477932-24-007810 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,118

F1 · shares: On December 1, 2024, the reporting person was awarded 7,302 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 2,434 units on each of December 1, 2024, January 1, 2025 and February 1, 2025, respectively, are also subject to further time-based vesting in a single installment on July 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

SEC source: 0001477932-24-007809 · form4.xml · nonDerivative · entry 1

Plummer Nicholas · CIK 0001880653 · GC, Volition Diagnostics

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,145

F1 · shares: On December 1, 2024, the reporting person was awarded 11,527 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,843 units, 3,842 units, and 3,842 units on each of December 1, 2024, January 1, 2025 and February 1, 2025, respectively, are also subject to further time-based vesting in a single installment on July 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.